Bafna Pharmaceuticals Reports Decline in Financial Performance for Q1 FY25

Aug 13 2024 09:12 PM IST
share
Share Via
Bafna Pharmaceuticals, a microcap company in the pharma industry, has reported a decline in its financial performance for the quarter ending June 2024. The company's stock has been rated as 'Strong Sell' by MarketsMojo, with a decrease in its overall financial health and a significant decline in profit before and after tax, as well as net sales.

Bafna Pharmaceuticals, a microcap company in the pharma industry, recently announced its financial results for the quarter ending June 2024. The results have been declared on August 13, 2024.

According to MarketsMOJO, a leading financial analysis platform, the stock call for Bafna Pharma is currently ‘Strong Sell’. This is based on the negative financial performance of the company in the last quarter.


The company’s score has fallen from -10 to -12 in the last three months, indicating a decline in its overall financial health. The profit before tax (PBT) has decreased by 192.1% to -0.88 crore, compared to the average PBT of the previous four quarters, which was 0.96 crore. This shows a very negative trend in the near term for PBT.


Similarly, the profit after tax (PAT) has also seen a significant decline of 120.1% to -0.37 crore, compared to the average PAT of the previous four quarters, which was 1.84 crore. The net sales for the quarter have also fallen by 12.7% to 33.29 crore, compared to the average net sales of the previous four quarters, which was 38.12 crore. This indicates a very negative trend in the near term for sales.


Based on the financial results, it can be observed that Bafna Pharmaceuticals is currently facing challenges in terms of its profitability and sales. Investors and experts are advised to closely monitor the company’s performance in the upcoming quarters. This news article is for informational purposes only and does not provide any recommendations or predictions for the future potential of the company.


{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News